Quadruple therapy for symptomatic spontaneous duodenal ulcer disease

Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.

AIM To investigate Helicobacter pylori eradication in duodenal ulcer patients with a new regimen, lansoprazole 30 mg daily for one or four weeks plus twice daily tetracycline 500 mg, clarithromycin 250 mg, and metronidazole 400 mg. BACKGROUND Spontaneous duodenal ulcer is regularly associated with H pylori, and permanent cure follows eradication of this bacterium. Numerous treatments have bee...

Pathogenesis and therapy of gastric and duodenal ulcer disease.

Despite the decreasing frequency of Helicobacter pylori-induced peptic ulcers, peptic ulcer disease remains a major clinical problem partly because nonsteroidal anti-inflammatory drug ulcers have increased in frequency. The reduction in nonsteroidal anti-inflammatory drug ulcers by use of selective cyclooxygenase-2 inhibitors will not eliminate the problem because of increased use of aspirin fo...

furazolidone-based quadruple therapy for eradication of helicobacter pylori infection in peptic ulcer disease

background helicobacter pylori is the main pathogenic factor for chronic gastritis and peptic ulcer disease. therefore, its successful eradication is important in the disease management. multiple first-line treatments have been employed; the eradication rates in the most successful regimens have been 75%-92%. primary bacterial resistance to antibiotics and patient compliance are two main cause ...

A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease.

PURPOSE Many of the currently used eradication regimens against Helicobacter pylori fail to cure the infection either due to antimicrobial resistance or to poor patient compliance. The infection leads to increased risk of developing potentially severe complications, such as gastric cancer. This study was aimed at assessing the efficacy and safety of a quadruple therapy with furazolidone for H. ...

Duodenal ulcer in sickle cell disease.